Clinical trial
Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With…
NCT00258193 · Ironwood Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00258193 |
|---|---|
| Title | Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS |
| Official title | A Phase 2 Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study of the Pharmacodynamic Effects of Orally Administered 100ug and 1000ug QD MD-1100 Acetate on Gastrointestinal Transit in Patients With Constipation Predominant Irritable Bowel Syndrome (C-IBS) |
| Lead sponsor | Ironwood Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome |
| Intervention type | Drug |
| Interventions | MD-1100 Acetate |
| Enrollment | 36 |
| Start date | Jan 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Nov 24, 2005 |
| Last update posted | Oct 20, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: